(Total Views: 628)
Posted On: 10/18/2020 8:18:48 PM
Post# of 145880
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: ClosetInvestor #61874
np big move would be to unblind the data.and thats why i mention inventory amount and the debt to samsung.but bioinvestor4 made an interesting point.
"Food for thought.... what if one of the secondary endpoints like clinical outcome at 14 or 28 days is what we hit a homerun on and not mortality at 28 days...
I never loved the mortality at 28 day endpoint as treatment improves so does the death rate. It made sense in May and June, not sure it makes sense now.
Could the DSMB be recommending something regarding one of the other endpoints?"
"Food for thought.... what if one of the secondary endpoints like clinical outcome at 14 or 28 days is what we hit a homerun on and not mortality at 28 days...
I never loved the mortality at 28 day endpoint as treatment improves so does the death rate. It made sense in May and June, not sure it makes sense now.
Could the DSMB be recommending something regarding one of the other endpoints?"
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)